Prostamol®Uno in treatment of the patients with benign prostatic hyperplasia (experience of 10 years)

Abstract

Catedra Urologie şi Nefrologie Chirurgicală USMF „N. Testemiţanu”, Spitalul Raional Edineţ; Secţia Urologie IMSP Spitalul Clinic Republican, Al V-lea Congres de Urologie, Dializă şi Transplant Renal din Republica Moldova cu participare internaţională (1-13 iunie 2011)Summary. During 10 years, between 2001-2011, 760 patients with BPH were treated with Prostamol®Uno, 320mg, daily. In this trial patients were assessed pre- and post- treatment with International Prostate Symptom Score (IPSS), the Quality of Life (QOL), values of PSA and volume of residual urine appreciated ecographically. The analysis of our data shows decrease in IPSS score, QOL and volume of residual urine with in 53,4 %, 57,5% and 48,7% respectively. Prostamol®Uno is one of election drug in conservative treatment of BPH